Salarius Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
DCOY$1.10-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months EndedSeptember 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Operating expenses: | ||||
| Research and development | $61,826 | $137,234 | $253,741 | $594,683 |
| General and administrative | 833,304 | 869,237 | 3,325,649 | 3,650,920 |
| Total operating expenses | 895,130 | 1,006,471 | 3,579,390 | 4,245,603 |
| Loss before other income (expense) | (895,130) | (1,006,471) | (3,579,390) | (4,245,603) |
| Interest income, net | 21,663 | 34,350 | 38,565 | 133,759 |
| Loss from continuing operations | (873,467) | (972,121) | (3,540,825) | (4,111,844) |
| Net loss | $(873,467) | $(972,121) | $(3,540,825) | $(4,111,844) |
| Loss per common share — basic and diluted (1) | $(1.81) | $(11.38) | $(14.35) | $(76.96) |
| Weighted-average number of common shares outstanding — basic and diluted (1) | 481,587 | 85,458 | 246,741 | 53,426 |
(1)Shares and per share amounts have been recast to reflect the 1-for-8 and 1-for-15 reverse stock split effected in June 14, 2024 and August 15, 2025, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.